Table 1.
Vaccines used in Romania, 27 December 2020–31 December 2021.
| Product (Authorization Date by the European Medicine Agency) |
Type of Vaccine | Vaccination Schedule | Indication |
|---|---|---|---|
| Comirnaty/Pfizer–BioNTech (21 December 2020) |
mRNA | 2 doses at 21 days apart *,** | People aged 12 and over (for the 5–12-year-old group, the pediatric vaccine became available in January 2022) |
| Spikevax/Moderna (06 January 2021) |
mRNA | 2 doses at 21 days apart *.** | People aged 12 and over |
| Vaxzevria/Oxford–AstraZeneca (29 January 2021) |
Viral vector | 2 doses at 4 to 12 weeks apart ** | People aged 18 and over |
| Janssen/Johnson&Johnson (11 March 2021) |
Viral vector | 1 dose ** | People aged 18 and over |
* For people with severe immunosuppression, 3 doses of the vaccine are recommended for the primary vaccination schedule (0, 21, 28 days for the Comirnaty/Pfizer–BioNTech vaccine, 0, 28, 28 days for the Spikevax/Moderna vaccine). Thus, in the case of severely immunosuppressed persons aged 12 years and over, the 3rd dose can be administered within the primary vaccination at least 28 days after the 2nd dose. Individuals falling within the following categories were considered severely immunocompromised persons and were recommended to receive three doses of the COVID-19 vaccine as their primary vaccination: patients with cancer in different stages of evolution with or without active treatment against it (chemotherapy, radiotherapy, molecular/biological treatment, etc.), patients with solid organ transplants or stem cell transplants with or without immunosuppressive treatment, and patients with congenital immunodeficiencies (DiGeorge syndrome, Wiskott–Aldrich syndrome, etc.) or with acquired immunodeficiencies (caused by HIV/AIDS or by a treatment). ** The booster dose could be administered at least 4 months after the primary vaccination (initially the recommendation was to administer each dose at least 6 months apart). A booster dose is especially recommended for people over 65 years of age, those with chronic conditions (regardless of age), people from medical and social centers, and those with a high risk of exposure (e.g., medical personnel). It is recommended an mRNA-based vaccine is used for the booster dose regardless of the vaccine used for the initial vaccination.